Document Detail

Salmeterol/fluticasone propionate: a review of its use in asthma.
MedLine Citation:
PMID:  19719334     Owner:  NLM     Status:  MEDLINE    
Salmeterol/fluticasone propionate (Seretide/Advair Diskus [dry powder inhaler] or Seretide/Advair inhalation aerosol [metered-dose inhaler]) is a fixed-dose combination inhalation agent containing a long-acting beta2-adrenoceptor agonist (LABA) plus a corticosteroid. In patients with symptomatic asthma, twice-daily salmeterol/fluticasone propionate maintenance therapy improves lung function and asthma symptoms to a greater extent than monotherapy with inhaled corticosteroids (ICS), such as fluticasone propionate, oral montelukast with or without fluticasone propionate, or sustained-release theophylline plus fluticasone propionate. The greater efficacy achieved with salmeterol/fluticasone propionate versus fluticasone propionate alone was sustained for 1 year in a well designed trial. Salmeterol/fluticasone propionate is also associated with a corticosteroid-sparing effect. Results of studies comparing fixed dosages of salmeterol/fluticasone propionate with formoterol/budesonide in adults and adolescents are equivocal. Twice-daily salmeterol/fluticasone propionate is associated with clinically meaningful improvements from baseline in health-related quality of life (HR-QOL), and improvements were greater than those reported with fluticasone propionate alone. Salmeterol/fluticasone propionate is generally well tolerated in adults, adolescents and children aged 4-11 years, and the fixed-combination inhaler ensures the appropriate use of a LABA in combination with an ICS. In cost-utility analyses in patients with uncontrolled asthma, salmeterol/fluticasone propionate compares favourably with fluticasone propionate alone or oral montelukast. Thus, salmeterol/fluticasone propionate provides an effective, well tolerated and cost-effective option for maintenance treatment in patients with asthma.
Kate McKeage; Susan J Keam
Related Documents :
15303644 - Is severity assessment after one hour of treatment better for predicting the need for a...
17623754 - Montelukast vs. inhaled low-dose budesonide as monotherapy in the treatment of mild per...
11167954 - Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in ...
15014704 - Depressive symptoms in inner-city children with asthma.
11742964 - Trials comparing early vs late extubation following cardiovascular surgery.
11262514 - Changes in cue reactivity following treatment for bulimia nervosa.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  69     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2009  
Date Detail:
Created Date:  2009-09-01     Completed Date:  2010-02-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  1799-828     Citation Subset:  IM    
Wolters Kluwer Health, Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Albuterol / adverse effects,  analogs & derivatives*,  economics,  pharmacology,  therapeutic use
Androstadienes / adverse effects,  economics,  pharmacology,  therapeutic use*
Anti-Asthmatic Agents / adverse effects,  economics,  pharmacology,  therapeutic use
Asthma / drug therapy*
Clinical Trials as Topic
Drug Combinations
Reg. No./Substance:
0/Androstadienes; 0/Anti-Asthmatic Agents; 0/Drug Combinations; 0/fluticasone, salmeterol drug combination; 18559-94-9/Albuterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Interactions between herbal medicines and prescribed drugs: an updated systematic review.
Next Document:  Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or kne...